SCROLL
SCROLL
About us
Nerviano Medical Sciences S.r.l is focused on discovery and clinical development of small molecule NCEs for oncology. The company takes innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients.
Our current pipeline consists of NCEs, which all originate from our well validated oncology drug discovery platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.
Nerviano Medical Sciences S.r.l combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharma (manufacturing).
A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib. Moreover, we are also developing a proprietary payload platform for generation of novel Antibody-Drug Conjugates (ADCs).
We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunies of promising assets for clinical development.
READ OUR STORY
Research
Our daily commitment
Research is the driving engine of our Company, with a longstanding experience in R&D and a proven track record of being able to perform innovative research and to bring molecules into clinical development up to registration.
Our research addresses different targets in key biological areas and molecular mechanisms that are crucial for onset and progression of diverse cancer types.
Our projects are supported by our scientific platforms, including the Kinase Platform and the ADC platform, that leverage our long standing expertise and technology approaches to generate economy of scale, allowing us to manage a broad project portfolio.
Clinical programs
We are exploiting our core Discovery engine to constantly develop new molecular entities with potential for “first in class” and “best in class”.
Our projects target a broad number of solid tumors and haematological indications, with a focus on biomarker selected patient populations. We are developing projects in house into clinical development in order to accelerate the clinical benefit for our patients.
DISCOVER MORE
Pipeline
Our pipeline includes outlicensed molecules in advanced clinical stage or already registered, as well as a broad portfolio of molecules at preclinical and clinical stage that are being developed by Nerviano Medical Sciences in different indications.
DISCOVER MORE
Latest News & Events
Entrectinib, the kinase inhibitor drug invented and initially developed by Nerviano Medical Sciences won the Prix Galien Italia 2021 Award in the Chemically Synthesized Drugs category
Nerviano, 5 November 2021
Entrectinib, the kinase inhibitor drug that was invented and initially developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has won the Prix Galien Italia 2021 award as an antitumor therapy with agnostic indication in the category of Chemically Synthesized Drugs.
(Click the title for the complete article)
Nerviano Medical Sciences Receives FDA “Study May Proceed” Letter for First-In-Human Phase 1 Clinical Trial under Its Investigational New Drug Application for NMS-03602173, a Dual IDH1/2 Inhibitor, in Advanced Solid Tumors
Nerviano, 22 October 2021
Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a pharmaceutical company developing innovative new chemical entities (NCE) for the treatment of cancers, today announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate NMS-03602173, a second-generation oral inhibitor of IDH1 and IDH2, in advanced solid tumors.
(Click the title for the complete article)
Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021
Nerviano, 29 September 2021
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue. The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts and members of Pharma Tech Outlook’s editorial board, NMS Group has come on top in terms of its ability to innovate in drug R&D process, and to meet client requirements, through support and customization.
(Click the title for the complete article)
Latest Events
Latest News
Need more information?